Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech)

https://doi.org/10.1016/j.jcv.2020.104511Get rights and content

Highlights

  • For IgG detection >14 days after symptoms onset was 100.0 % for all assays.

  • Specificity for IgG was greater than 98 % for CLIA and LFIA compared to ELISA.

  • LFIA (NG-Test®) is reliable and accurate to diagnose SARS-CoV-2 infection.

  • Best agreement was observed between CLIA and LFIA assays (97 %; k = 0.936).

Abstract

Background

The emergence of new SARS-CoV-2 has promoted the development of new serological tests that could be complementary to RT-PCR. Nevertheless, the assessment of clinical performances of available tests is urgently required as their use has just been initiated for diagnose.

Objectives

The aim of this study was to assess the performance of three immunoassays for the detection of SARS-CoV-2 antibodies.

Methods

Two automated immunoassays (Abbott SARS-CoV-2 CLIA IgG and Euroimmun Anti-SARS-CoV-2 ELISA IgG/IgA assays) and one lateral flow immunoassay (LFIA NG-Test® IgG-IgM COVID-19) were tested. 293 specimens were analyzed from patients with a positive RT-PCR response, from patients with symptoms consistent with COVID-19 but exhibiting a negative response to the RT-PCR detection test, and from control group specimens. Days since symptoms onset were collected from clinical information sheet associated with respiratory tract samples.

Results

Overall sensitivity for IgG was equivalent (around 80 %) for CLIA, ELISA and LFIA. Sensitivity for IgG detection, >14 days after onset of symptoms, was 100.0 % for all assays. Overall specificity for IgG was greater for CLIA and LFIA (more than 98 %) compared to ELISA (95.8 %). Specificity was significantly different between IgA ELISA (78.9 %) and IgM LFIA (95.8 %) (p < 0.05). The best agreement was observed between CLIA and LFIA assays (97 %; k = 0.936).

Conclusion

Excellent sensitivity for IgG detection was obtained >14 days after onset of symptoms for all immunoassays. Specificity was also excellent for IgG CLIA and IgG LFIA. Our study shows that NG-Test® is reliable and accurate for routine use in clinical laboratories.

Keywords

SARS-CoV-2
COVID-19
Performance
Automated immunoassays
Lateral flow immunoassay

Cited by (0)

1

These authors equally participated to the study.

View Abstract